Neurochlore Overview
- Founded
-
2011
- Status
-
Private
- Latest Deal Type
-
2ndary - Private
- Investors
-
3
Neurochlore General Information
Description
Developer of a neuro-therapeutic treatment platform intended to treat autism spectrum disorders. The company's platform develops new therapeutic approaches to ameliorate neurological and psychiatric diseases based on the regulation of the brain's electrical activity around a wide range of animal models of ASD and syndromes with associated autism, enabling patients to modulate intracellular chloride.
Contact Information
Website
www.neurochlore.fr
Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Primary Industry
Other Healthcare Technology Systems
Primary Office
- 163 Avenue de Luminy
- Zone Luminy Biotech, Case 922, Cedex 09
- 13273 Marseille
- France
Neurochlore Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Secondary Transaction - Private | 01-Aug-2022 | 00.000 | Completed | Clinical Trials - Phase 3 | ||
| 3. Early Stage VC | 18-Jul-2013 | 00.000 | 00.000 | 00.00 | Completed | Startup |
| 2. Accelerator/Incubator | Completed | Startup | ||||
| 1. Grant | 12-Nov-2012 | Completed | Startup |
Neurochlore Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A Preferred | 0,000 | 000.000000 | 00000.00 | 00000.00 | 00 | 00000.00 | 00.000 | |
| Ordinary | 000 | 000.000000 | 000.00 | 000.00 | 00 | 000.00 | 0.000 |
Neurochlore Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Neurochlore Patents
Neurochlore Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20220370390-A1 | Liquid oral formulation of bumetanide | Pending | 31-Oct-2019 | 0000000000 | |
| EP-4051232-A1 | Liquid oral formulation of bumetanide | Pending | 31-Oct-2019 | 0000000000 | |
| CA-3158575-A1 | Liquid oral formulation of bumetanide | Pending | 31-Oct-2019 | A61K31/196 |
Neurochlore Executive Team (3)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Constance Ben-Ari | Co-Chief Executive Officer | ||
| Yehezkel Ben-Ari Ph.D | Co-Founder, Co-Chief Executive Officer, President & Board Member |
Neurochlore Board Members (2)
| Name | Representing | Role | Since |
|---|---|---|---|
| Eric Lemonnier Ph.D | Neurochlore | Co-Founder & Board Member | 000 0000 |
| Nouchine Hadjikhani Ph.D | Neurochlore | Co-Founder & Board Member | 000 0000 |
Neurochlore Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| L'Agence Nationale de la Recherche | Government | 000 0000 | 000000 0 | ||
| Grand Luminy | Accelerator/Incubator | Minority | 000 0000 | 000000 0 | |
| Incubateur Impulse | Accelerator/Incubator | 000 0000 | 000000 0 |